Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition